Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes Aaron.

Slides:

Advertisements

Similar presentations

Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States David B. Seifer, M.D., Valerie.

Advertisements

Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles Ryan G. Steward,

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Men's meat intake and treatment outcomes among couples undergoing assisted reproduction Wei Xia, M.D., Ph.D., Yu-Han Chiu, M.D., Paige L. Williams, Ph.D.,

Efficacy of predictive models for polycystic ovary syndrome using serum levels of two antimüllerian hormone isoforms (proAMH and AMHN,C) Michael W. Pankhurst,

Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice Laura Detti, M.D., Rebecca A. Uhlmann,

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women.

Pregnancies of unknown location after in vitro fertilization: minimally invasive management with Karman cannula aspiration Paula Brady, M.D., Anthony.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Association of physical activity in the past year and immediately after in vitro fertilization on pregnancy Kelly R. Evenson, Ph.D., M.S., Kathryn C.

Patient-tailored ovarian stimulation for in vitro fertilization

Piotr Zareba, M. D. , M. P. H. , Daniela S. Colaci, M. D. , M. Sc

Antimüllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause Linlin Cui, M.D., Ph.D., Yingying.

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women Carlos Iglesias, M.D., Manish Banker, M.D.,

Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women Ellen W. Freeman, Ph.D.,

Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for.

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count Simone L. Broer, B.Sc., Ben Willem J.

Iris G. Insogna, M. D. , Malinda S. Lee, M. D. , M. B. A. , Rebecca M

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Two interesting cases of ovarian pregnancy after in vitro fertilization–embryo transfer and its successful laparoscopic management Selvaraj Priya, M.D.,

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Deleterious effect of tobacco on IVF outcome and ovarian reserve as reflected by serum anti mullerian hormone (AMH) P. Barriere, T. Freour, D. Masson,

Modification of the Beckman-Coulter second-generation enzyme-linked immunosorbent assay protocol improves the reliability of serum antimüllerian hormone.

Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis Cui Hong Zheng, M.D., Ph.D.,

Race/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling.

A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization Laura Detti, M.D., Daniel B. Williams, M.D., Jared.

Association between prior appendectomy and/or tonsillectomy in women and subsequent pregnancy rate: a cohort study Li Wei, Ph.D., Thomas MacDonald, M.D.,

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis Laura P. Smith, M.D.,

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis Reshef Tal,

Using the Society for Assisted Reproductive Technology Clinic Outcome System morphological measures to predict live birth after assisted reproductive.

Ovarian hyperstimulation secondary to ectopic secretion of follicle-stimulating hormone. Literature review prompted by a case Jorge Burgos, M.D., Patricia.

Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles Karin.

Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro.

Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection Dorothea M.

Thomas M. D’Hooghe, M. D. , Ph. D. , Bénédicte Denys, M. D

Orhan Bukulmez, M. D. , Bruce R. Carr, M. D. , Kathleen M. Doody, M. D

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

One last chance for pregnancy: a review of 2,705 in vitro fertilization cycles initiated in women age 40 years and above Sigal Klipstein, M.D., Meredith.

Aaron K. Styer, M. D. , Diane L. Wright, Ph. D. , H. C. L. D. , Anne M

Serum and follicular fluid monocyte chemotactic protein-1 levels are elevated in obese women and are associated with poorer clinical pregnancy rate after.

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

János Urbancsek, M. D. , Ph. D. , Erik E. Hauzman, M. D. , Ana R

A randomized clinical trial to determine optimal infertility treatment in older couples: the Forty and Over Treatment Trial (FORT-T) Marlene B. Goldman,

Cost and efficacy comparison of in vitro fertilization and tubal anastomosis for women after tubal ligation Lauren B. Messinger, M.D., Connie E. Alford,

Clinical and biologic evaluation of ovarian function in women treated by bone marrow transplantation for various indications during childhood or adolescence

Sedigheh Borna, M.D., Azita Nasery, M.D. Fertility and Sterility

Impact of subclinical hypothyroidism in women with recurrent early pregnancy loss Lia A. Bernardi, M.D., Ronald N. Cohen, M.D., Mary D. Stephenson, M.D.,

Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.

Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr Murat Arslan, M.D.,

Aline Ketefian, M. D. , Jianfang Hu, Ph. D. , Alfred A. Bartolucci, Ph

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories Melissa C. Yih, M.D.,

Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D

In vitro sildenafil citrate use as a sperm motility stimulant

Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian.

Urinary paraben concentrations and in vitro fertilization outcomes among women from a fertility clinic Lidia Mínguez-Alarcón, Ph.D., Yu-Han Chiu, M.D.,

A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.

Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization Rongrong Tan, M.M.Sc., Danhua Pu,

Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:

The cumulative probability of liveborn multiples after in vitro fertilization: a cohort study of more than 10,000 women Beth A. Malizia, M.D., Laura.

Maternal serum screening markers and nuchal translucency measurements in in vitro fertilization pregnancies: a systematic review Andrea Lanes, M.Sc.,

Presentation transcript:

Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes Aaron K. Styer, M.D., Audrey J. Gaskins, Sc.D., Paula C. Brady, M.D., Patrick M. Sluss, Ph.D., Jorge E. Chavarro, M.D., Sc.M., Sc.D., Russ B. Hauser, M.D., M.P.H., Sc.D., Thomas L. Toth, M.D. Fertility and Sterility Volume 104, Issue 5, Pages 1153-1161.e7 (November 2015) DOI: 10.1016/j.fertnstert.2015.07.1161 Copyright © 2015 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Median serum AMH levels during controlled ovarian stimulation by tertile of rate of AMH decline. T1 = tertile 1; T2 = tertile 2; T3 = tertile 3; AMH = antimüllerian hormone; COH = controlled ovarian hyperstimulation. Pretreatment AMH was available in a subset of women (n = 26). Fertility and Sterility 2015 104, 1153-1161.e7DOI: (10.1016/j.fertnstert.2015.07.1161) Copyright © 2015 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 1 Calibration curves for serum AMH (manufacturer specification versus study modifications). AMH = antimüllerian hormone; SOP = curve generated from manufacturer’s instructions; modified = curve generated from modifications of manufacturer’s protocol in this study. Fertility and Sterility 2015 104, 1153-1161.e7DOI: (10.1016/j.fertnstert.2015.07.1161) Copyright © 2015 American Society for Reproductive Medicine Terms and Conditions

Supplemental figure 2 Dynamic serum AMH levels during controlled ovarian hyperstimulation by tertile of rate of AMH decline. T1 = tertile 1; T2 = tertile 2; T3 = tertile 3. Fertility and Sterility 2015 104, 1153-1161.e7DOI: (10.1016/j.fertnstert.2015.07.1161) Copyright © 2015 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 3 Relationship between tertiles of AMH change during COH and clinical pregnancy following IVF in the entire cohort and stratified by age. COH = controlled ovarian hyperstimulation; IVF = in vitro fertilization. Rate of AMH change tertiles: T1, T2, T3. Fertility and Sterility 2015 104, 1153-1161.e7DOI: (10.1016/j.fertnstert.2015.07.1161) Copyright © 2015 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 4 The trend of serum estradiol (E2) concentrations during controlled ovarian stimulation by tertile of rate of E2 change. Unique colors used to represent respective rate of serum E2 change. T1 = tertile 1; T2 = tertile 2; T3 = tertile 3. Fertility and Sterility 2015 104, 1153-1161.e7DOI: (10.1016/j.fertnstert.2015.07.1161) Copyright © 2015 American Society for Reproductive Medicine Terms and Conditions